Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics
- Tuesday, July 5, 2022, 7:14
- Environment
- Add a comment
– Precigen enters into agreement to sell wholly-owned subsidiary Trans Ova Genetics to URUS for $170 million in upfront cash and up to $10 million earn-out over two years; close expected in Q3 2022 – – Transaction, upon closing, will solidify balance sheet and the Company intends to pay…
About the Author
adminasapcorp has written 41546 stories on this site.